London – Researchers from University College London (UCL), working in collaboration with Great Ormond Street Hospital and Moorfields Eye Hospital, have identified a previously under-recognised role for B cells in the development of uveitis associated with juvenile idiopathic arthritis (JIA), according to a study published in Nature Communications on Monday.
The findings challenge the longstanding assumption that T cells are the primary drivers of JIA-associated uveitis and suggest potential new avenues for treatment in children at risk of permanent vision loss.
JIA is the most common form of arthritis in children under 16, affecting approximately one in every 1,000 in the United Kingdom. Around 30% of these children also develop uveitis, an inflammatory eye condition that can progress silently, leading to complications such as cataracts, scarring, and lifelong impairment of vision. Despite current treatment options, studies indicate that up to a third of children with JIA-uveitis experience some degree of permanent vision loss by adulthood.
Read also: Quebec Immigration Protests Spark Backlash Over PEQ Cut
The UCL-led research team combined analyses of blood samples with rare tissue samples taken directly from the eyes of children undergoing surgery for uveitis-related complications, such as cataracts. Senior author Dr Elizabeth Rosser, associate professor at UCL, explained the methodology. “We examined rare samples taken directly from the eyes of children with uveitis, who were already undergoing surgery for related complications such as cataracts,” she said. “While results from animal studies cannot be directly applied to children, they can help identify immune pathways that may be important in disease. Following careful clinical trials, we hope that existing treatments could one day be adapted or tested for this sight-threatening condition.”
The analysis revealed consistently elevated levels of a specific subset of B cells in children with JIA-uveitis. Subsequent experiments using a mouse model demonstrated that blocking communication between B and T cells reduced eye inflammation. These findings suggest that therapies targeting both cell types could be more effective than current treatments, potentially limiting or preventing the development of sight-threatening damage in affected children.
Dr Rosser noted that while further clinical trials are necessary to confirm the findings in humans, the research opens a new direction for therapeutic strategies. “Identifying the role of B cells adds to our understanding of the immune mechanisms underlying JIA-uveitis,” she said. “This could guide the development or repurposing of treatments to improve outcomes for children at risk of vision loss.”
The study also highlights the value of rare ocular samples in advancing knowledge of pediatric eye diseases. By examining tissue directly from affected eyes, researchers were able to identify immune processes that may not be apparent from blood tests alone, offering insights into disease mechanisms and potential intervention points.
Read more: US Envoy Waltz Confirms Partial Settlement Of UN Arrears
Angela Hind, chief executive of the Medical Research Foundation, emphasised the significance of the findings for affected children and their families. “For reasons we still don’t fully understand, children with arthritis can also develop uveitis, and for many, the disease does not respond to current treatments, with devastating consequences for their sight and long-term health,” she said. “This research has uncovered vital new insights into the immune responses driving eye inflammation, highlighting the importance of medical research in improving outcomes for children with serious and potentially blinding eye diseases.”
The research underscores the complexity of immune responses in pediatric inflammatory conditions and the need for tailored approaches to treatment. Current therapies for JIA-uveitis include corticosteroids and immunosuppressive drugs, but limitations in efficacy and side-effect profiles leave a significant proportion of children at risk of permanent visual impairment.
By identifying B cells as a contributing factor, the study raises the possibility of applying existing therapies that target B cells—currently used in other autoimmune conditions—for children with JIA-uveitis. However, Dr Rosser cautioned that clinical trials will be necessary to determine safety and effectiveness before such treatments can be recommended.
The study represents a collaboration across multiple institutions and specialties, reflecting a growing trend in pediatric research to combine clinical expertise, laboratory analysis, and translational science. Great Ormond Street Hospital provided surgical samples, while Moorfields Eye Hospital contributed ophthalmologic expertise and patient follow-up data.
Experts in pediatric rheumatology and ophthalmology have welcomed the findings as a step toward better understanding and managing a condition that has historically been challenging to treat. “Children with JIA-uveitis are at high risk of complications, and any research that clarifies the immune mechanisms involved is a positive development,” said Dr Maria Thompson, a consultant pediatric rheumatologist not involved in the study.
Looking ahead, the UCL team plans to conduct additional studies to map B cell activity over time and explore potential drug targets. These studies will aim to validate whether blocking B and T cell interactions can safely reduce inflammation and prevent vision loss in children with JIA-uveitis.